N 6-methyladenosine (m 6 A) is the most extensive studied RNA modification across various species, and the important effect of m 6 A modification in immune system has been revealed in distinct ...

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA ...

Targeting mRNA expression presents a promising approach in the treatment of haploinsufficiency disorders, offering a new avenue for therapeutic intervention. While gene expression changes are commonly ...

An international team led by Monash University researchers has uncovered the genetic code governing the way genetic mutations ...

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...

The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...

Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable ...

Wacker Biotech, a CDMO, began a strategic collaboration with Boston-based RNAV8 Bio aimed at progressing the development and production of mRNA-based advanced therapies for the biopharma industry.